scholarly journals A CASE REPORT ON ILD-NSIP, PULMONARY ARTERIAL HYPERTENSION IN ASSOCIATION WITH SJOGRENS'S SYNDROME

2020 ◽  
pp. 1-2
Author(s):  
Shivani Singh Thakur ◽  
Chittipolu Shirisha
Keyword(s):  
Pulmonary Embolism ◽  
Pulmonary Hypertension ◽  
Case Report ◽  
Disease Association ◽  
Diffuse Parenchymal Lung Disease ◽  
Pulmonary Arterial ◽  
The Common ◽  
Tracheobronchial Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Sjogren syndrome with various pulmonary symptoms and the common manifestations are diffuse parenchymal lung disease and tracheobronchial disease. Association with ILD-NSID, pulmonary embolism, pulmonary hypertension are rare. We experienced a case of ILD-NSIP accompanied with sjogren’s syndrome and are treated further and we present the details of the case here in.

scholarly journals Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea

2020 ◽  
Vol 10 (1) ◽  
pp. 204589401989191 ◽  
Author(s):  
Richard H. Zou ◽  
William D. Wallace ◽  
S. Mehdi Nouraie ◽  
Stephen Y. Chan ◽  
Michael G. Risbano
Keyword(s):  
Pulmonary Hypertension ◽  
Lung Disease ◽  
Vascular Disease ◽  
Pulmonary Function Tests ◽  
Pulmonary Vascular Disease ◽  
Chronic Obstructive ◽  
Exertional Dyspnea ◽  
Pulmonary Arterial ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Exercise pulmonary hypertension is an underappreciated form of physical limitation related to early pulmonary vascular disease. A low diffusing capacity of lungs for carbon monoxide (DLco) can be seen in patients with resting pulmonary hypertension as well as parenchymal lung disease. It remains unclear whether low DLco% identifies early pulmonary vascular disease. We hypothesize that a reduced DLco% differentiates the presence of exercise pulmonary hypertension in patients with parenchymal lung disease. Fifty-six patients referred for unexplained exertional dyspnea with pulmonary function tests within six months of hemodynamic testing underwent exercise right heart catheterization. Exclusion criteria included resting pulmonary arterial or venous hypertension. Receiver operator characteristic curve determined the optimal DLco% cutoffs based on the presence or absence of parenchymal lung disease. Twenty-one (37%) patients had parenchymal lung disease, most common manifesting as chronic obstructive lung disease or interstitial lung disease. In patients with parenchymal lung disease, a DLco of 46% demonstrated 100% sensitivity and 73% specificity for detecting exercise pulmonary hypertension. In patients without parenchymal lung disease, a DLco of 73% demonstrated 58% sensitivity and 94% specificity for detecting exercise pulmonary hypertension. In both cohorts, DLco% below the optimum cutoffs were associated with higher peak mean pulmonary arterial pressure and peak total pulmonary resistance consistent with the hemodynamic definition of exercise pulmonary hypertension. Patients with a DLco < 46% were more often treated with pulmonary vasodilators and had a trend to higher mortality and lung transplant. DLco% is a simple non-invasive screening test for the presence of exercise pulmonary hypertension in our mixed referral population with progressive exertional dyspnea. DLco < 46% with parenchymal lung disease and DLco < 73% without parenchymal lung disease may play a role in differentiating the presence of pulmonary vascular disease prior to invasive hemodynamic testing.

scholarly journals Pulmonary Hypertension in Parenchymal Lung Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-14 ◽  
Author(s):  
Iraklis Tsangaris ◽  
Georgios Tsaknis ◽  
Anastasia Anthi ◽  
Stylianos E. Orfanos
Keyword(s):  
Pulmonary Hypertension ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Idiopathic Pulmonary Arterial Hypertension ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Diffuse Parenchymal Lung Diseases ◽  
Pulmonary Arterial ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Idiopathic pulmonary arterial hypertension (IPAH) has been extensively investigated, although it represents a less common form of the pulmonary hypertension (PH) family, as shown by international registries. Interestingly, in types of PH that are encountered in parenchymal lung diseases such as interstitial lung diseases (ILDs), chronic obstructive pulmonary disease (COPD), and many other diffuse parenchymal lung diseases, some of which are very common, the available data is limited. In this paper, we try to browse in the latest available data regarding the occurrence, pathogenesis, and treatment of PH in chronic parenchymal lung diseases.

scholarly journals Cell-derived microparticles and the lung

2016 ◽  
Vol 25 (141) ◽  
pp. 266-277 ◽  
Author(s):  
Dario Nieri ◽  
Tommaso Neri ◽  
Silvia Petrini ◽  
Barbara Vagaggini ◽  
Pierluigi Paggiaro ◽  
...  
Keyword(s):  
Nuclear Factor Κb ◽  
Parental Cell ◽  
Cardiovascular Comorbidities ◽  
Diffuse Parenchymal Lung Disease ◽  
Pulmonary Arterial ◽  
Kinase Phosphorylation ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Cell-derived microparticles are small (0.1–1 μm) vesicles shed by most eukaryotic cells upon activation or during apoptosis. Microparticles carry on their surface, and enclose within their cytoplasm, molecules derived from the parental cell, including proteins, DNA, RNA, microRNA and phospholipids. Microparticles are now considered functional units that represent a disseminated storage pool of bioactive effectors and participate both in the maintenance of homeostasis and in the pathogenesis of diseases. The mechanisms involved in microparticle generation include intracellular calcium mobilisation, cytoskeleton rearrangement, kinase phosphorylation and activation of the nuclear factor-κB. The role of microparticles in blood coagulation and inflammation, including airway inflammation, is well established inin vitroand animal models. The role of microparticles in human pulmonary diseases, both as pathogenic determinants and biomarkers, is being actively investigated. Microparticles of endothelial origin, suggestive of apoptosis, have been demonstrated in the peripheral blood of patients with emphysema, lending support to the hypothesis that endothelial dysfunction and apoptosis are involved in the pathogenesis of the disease and represent a link with cardiovascular comorbidities. Microparticles also have potential roles in patients with asthma, diffuse parenchymal lung disease, thromboembolism, lung cancer and pulmonary arterial hypertension.

Sign in / Sign up

Export Citation Format

Share Document